Retatrutide (LY3437943) Research Reference
This evidence index separates verifiable identity and registered research from commercial claims. It is written for qualified laboratory teams evaluating Retatrutide as an in-vitro reference material.
Last reviewed:
Warning: These materials are strictly for in-vitro laboratory research. Not for human or veterinary use.
Identity and aliases
Retatrutide is also identified as LY3437943 in primary study records. Keeping the development code and common name together helps laboratory teams distinguish the entity from adjacent GLP-1 and GIP pathway references.
Receptor-pathway context
Peer-reviewed publications describe Retatrutide as an agonist studied across GIP, GLP-1 and glucagon receptor pathways. This receptor description is a research classification, not evidence that a laboratory reference material is suitable for human or veterinary use.
Research status
ClinicalTrials.gov records multiple registered studies under LY3437943, including NCT04881760 and the direct Retatrutide-versus-Tirzepatide study NCT06662383. Registry inclusion documents that research exists; it does not establish regulatory approval, individual suitability or a medical recommendation.
Documentation hierarchy
For material evaluation, use the current product specification and batch-specific documentation. A scientific publication identifies the studied molecule; it does not verify the identity, purity or handling history of a separate commercial batch.
Research references
- Retatrutide for the Treatment of Obesity — New England Journal of Medicine, DOI 10.1056/NEJMoa2301972
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight — ClinicalTrials.gov, NCT05929066
- Retatrutide Compared to Tirzepatide in Adults Who Have Obesity — ClinicalTrials.gov, NCT06662383
Reference questions
Does published research prove that a supplied batch matches a study material?
No. Publications and trial registries describe research entities and protocols. Batch identity and analytical characteristics must be assessed from the documentation for that specific batch.
Is this page medical guidance?
No. It is an evidence index for qualified in-vitro laboratory work and does not provide dosing, administration, treatment or human-use guidance.